Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.44 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19523758 | 1.00 | HTT (0.63) | HTTTSHRKDM4ELIMK1LMNA | |
| SCHEMBL15236810 | 0.90 | TSHR (0.51) | HTTTSHRKDM4ELIMK1LMNA | |
| SCHEMBL15236807 | 0.90 | TSHR (0.51) | HTTTSHRKDM4ELIMK1LMNA | |
| SCHEMBL13644100 | 0.85 | HTT (0.64) | HTTTSHRKDM4ELIMK1LMNA | |
| SCHEMBL17850662 | 0.83 | LIMK1 (0.70) | HTTTSHRKDM4ELIMK1LMNA | |
| SCHEMBL14459722 | 0.83 | LIMK1 (0.70) | HTTTSHRKDM4ELIMK1LMNA | |
| SCHEMBL5630969 | 0.83 | CSNK2A2 (0.51) | HTTTSHRKDM4ELIMK1LMNA | |
| SCHEMBL14459798 | 0.82 | LIMK1 (0.54) | HTTTSHRKDM4ELIMK1LMNA | |
| SCHEMBL23254239 | 0.81 | ALDH1A1 (0.47) | HTTTSHRKDM4ELIMK1LMNA | |
| SCHEMBL18863898 | 0.80 | HTT (0.43) | HTTTSHRKDM4ELIMK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3239154-A1 | IRAK INHIBITORS AND USES THEREOF | Nimbus Iris, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2663312-B1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20160296524-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160296524-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2016-10-13 | — | — | US | disclosed |
| US-9340554-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340554-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150025093-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20150025093-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20120283238-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283238-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| WO-2012097013-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2012-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025093-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HTT 3378/4885TSHR 3940/4885KDM4E 522/4885 |
| US-20160296524-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HTT 3378/4885TSHR 3940/4885KDM4E 522/4885 |
| US-20120283238-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HTT 3378/4885TSHR 3940/4885KDM4E 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.